

**Control/Tracking Number:** 2010-A-2234-ASM-ICAAC

**Activity:** Abstract

**Current Date/Time:** 5/7/2010 7:54:07 AM

## Survey of Antibiotic Prescriptions (SPA) in a Network of French Hospitals in 2009

**Author Block:** J. ROBERT<sup>1</sup>, Y. PEAN<sup>2</sup>, J. P. BEDOS<sup>3</sup>, E. VARON<sup>4</sup>, J. P. STAHL<sup>5</sup>, A. LEPAPE<sup>6</sup>, J. P. BRU<sup>7</sup>, X. BERTRAND<sup>8</sup>, R. GAUZIT<sup>9</sup>, And The Spilf;

<sup>1</sup>UFR Médecine PM Curie - ONERBA, PARIS, France, <sup>2</sup>IMM, PARIS, France, <sup>3</sup>CH, Versailles, France, <sup>4</sup>HEGP, PARIS, France, <sup>5</sup>CHU, Grenoble, France, <sup>6</sup>CHU, LYON SUD, France, <sup>7</sup>CH, ANNECY, France, <sup>8</sup>CHU, BESANCON, France, <sup>9</sup>Hotel Dieu, PARIS, France.

**Abstract: Background.** Analysis of antimicrobial prescription according to patients characteristics is of major interest to prevent resistance.

**Method.** One-day prevalence survey in a sample of hospitalized patients in 38 voluntary French hospitals by using a questionnaire adapted from ESAC.

**Results.** A total of 3964 patients were surveyed (39% in medicine, 29% in surgery, 12% in ICUs, and 20% in other departments), including 1276 (32%) with an antimicrobial treatment. Among the latter, 35% received B-lactams+inhibitors, 24% fluoroquinolones (FQ), 22% 3<sup>rd</sup> generation cephalosporins. 51% were treated for community infections, and 39% for nosocomial infections (10% unknown), including 22% and 34% (p<.01) for >7 days at the date of survey, respectively. 34% of the patients with community infections received >1 drug vs 48% among those with nosocomial infections (p<.01). A total of 23% of patients with antibiotics did not have any microbiological sample drawn (64% among community infections, 24% among nosocomial infections, and 12% among infections of undetermined origin), including 19% with a duration of treatment >7 days at the date of survey. Patients with proven MDR bacteria (8%) were significantly treated with > 1 drug, for a longer duration of time than others.

**Conclusion.** Despite a large dissemination of guidelines during the last years, 1/4 of patients with community infections received >7 days of treatment, and 1/3 more than 1 drug. More surprisingly, a large proportion of all patients received antimicrobials for more than 1 week without documented infection. Finally, the large proportion of patients receiving FQ should be put in perspective with increased resistance rates. Consequently, education and antibiotic stewardship should be implemented in French hospitals.

**Author Disclosure Information:** J. Robert, None..

Y. Pean, None..

J. P. Bedos, None..

E. Varon, None..

J. P. Stahl, None..

A. Lepape, None..

J. P. Bru, None..

X. Bertrand, None..

R. Gauzit, None.

**Category (Complete):** K

**Keyword (Complete):** surveillance ; antibiotic use

**Additional Information (Complete):**

**\*Please choose one of the following after you have read the statements above:**

Agree

**\*SIGNATURE: I have carefully read and considered each item in this form, and have completed it to the best of my ability. (Please type your name in the box below.)**

: J robert

**\*Pleaes choose one of the choices:** I agree to the above for Audio and Video.

**\*Please select your presentation method:** PC based computer only|Macintosh computer only|Embedded audio with a PC based computer.

**Awards & Travel Grants (Complete):**

**Please make a choice below:**

I do not wish to be considered.

**Please make a choice below:**

I do not wish to be considered.

**Please make a choice below:**

I do not wish to be considered.

**Please make a choice below:**

I do not wish to be considered.

**Please make a choice below:**

I do not wish to be considered.

**Status:** Complete

[American Society for Microbiology](#)

1752 N Street N.W.

Washington, D.C. 20036

Phone: (202) 737-3600

If you encounter any technical difficulties, please Technical Support: [OASIS Helpdesk](#) or call 217-398-1792

Leave OASIS Feedback!

Powered by [OASIS](#), The Online Abstract Submission and Invitation System <sup>SM</sup>  
© 1996 - 2010 [Coe-Truman Technologies, Inc.](#) All rights reserved.

